Table IV.
Comparison of present study with published descriptive studies on COVID-19
| Study | Guan et al9 (n=1099) | Chen et al13 (n=99) | Huang et al10 (n=41) | Wang et al11 (n=138) | Richardson et al20 (n=5700) | Current study (n=144) |
|---|---|---|---|---|---|---|
| Age (yr) | 47 | 55.5 | 49 | 56 | 63 (52-75)# | 40.1 (13.1)* |
| Males, n (%) | 637 (58.1) | 67 (68) | 30 (73) | 75 (54.3) | 3437 (60.3) | 134 (93.1) |
| Exposure characteristics, n (%) | ||||||
| Living in Wuhan | 483 (43.9) | NR | NR | NR | NR | Community hotspots 119 (82.6) Domestic travel to affected areas 111 (77.1) |
| Contact with wildlife | 13 (1.9) | 49 (49) | 27 (66) | 12 (8.7) | NR | |
| Recently visited Wuhan | 193 (31.3) | NR | NR | NR | NR | |
| Contact with Wuhan residents | 442 (72.3) | NR | NR | NR | NR | |
| Smoking history, n (%) | 158 (14.6) | NR | 3 (7) | NR | 558 (15.6) | 9 (6.3) |
| Comorbidities, n (%) | ||||||
| Any | 261 (23.7) | 50 (51) | 13 (32) | 64 (46.4) | NR | NR |
| Cardiovascular | 27 (2.5) | 40 (40) | 6 (15) | 20 (14.5) | NR | 1 (0.7) |
| Neurological | 15 (1.4) | 1 (1) | NR | 7 (2.9) | NR | 1 (0.7) |
| Hypertension | 165 (15) | NR | 6 (15) | 43 (31.2) | 3026 (56.6) | 3 (2.1) |
| Digestive system disease | 23 (2.1) | 11 (11) | 1 (2) | 4 (2.9) | NR | NR |
| Endocrine system disease | 81 (7.4) | 13 (13) | 8 (20) | 14 (10.1) | 1808 (33.8) | 16 (11.1) |
| Malignant tumour | 10 (0.9) | 1 (1) | 1 (2) | 10 (7.2) | NR | NR |
| Pulmonary disease | 12 (1.1) | 1 (1) | 1 (2) | 4 (2.9) | NR | 3 (2.1) |
| Obesity | NR | NR | NR | NR | 1737 (41.7) | NR |
| Fever, n (%) | 975 (88.7) | 82 (83) | 40 (98) | 136 (98.6) | 1734 (30.7) | 25 (17.4) |
| Cough, n (%) | 745 (67.8) | 81 (82) | 31 (76) | 82 (59.4) | NR | 50 (34.7) |
| Nasal symptoms/throat irritation, n (%) | 153 (13.9) | 5 (5) | NR | 24 (17.4) | NR | 31 (21.5) |
| Sputum, n (%) | NR | NR | 11 (28) | 37 (26.8) | NR | 5 (3.5) |
| Dyspnoea, n (%) | 205 (18.7) | 31 (31) | 22 (55) | 43 (31.2) | NR | 8 (5.6) |
| Diarrhoea, n (%) | 42 (3.8) | 2 (2) | 1 (3) | 14 (10.1) | NR | 4 (2.8) |
| Severe disease, n (%) | 173 (15.74) | 23 (23) | 12 (29) | 36 (26) | 1584 (27.8) | 4 (2.8) |
| Lymphopenia, n (%) | 731 (83.2) | 35 (35) | 26 (63) | NR | 3387 (60) | 9 (6.3) |
| Progression to severe disease, n (%) | 173 (15.74) | 23 (23) | 13 (32) | 36 (26) | NR | 5 (3.5) |
| Oxygen supplementation, n (%) | 454 (41.3) | 75 (76) | 27 (66) | 106 (76.81) | 1584 (27.8) | 5 (3.5) |
| Mechanical ventilation, n (%) | 67 (6.1) | 17 (17) | 14 (34) | 32 (23.2) | 320 (12.2) | 1 (0.8) |
| HCQ administration, n (%) | NR | NR | NR | NR | NR | 27 (18.7) |
| Other specific drugs (%) | Oseltamivir (35.8) Antifungals (2.8) Steroids (18.6) | Antivirals (76) Antifungal (15) Steroids (19) Antibiotics (71) IVIg (27) | Antivirals (93) Antibiotics (100) Steroids (22) | Antivirals (89.9) Steroids (44.9) | NR | Azithromycin (20.1)Antitubercular therapy (0.7) |
| Mortality (%) | 1.4 | 11 | 15 | 4.3 | 21 | 1.4 |
All values expressed as number (%); median (IQR)#or mean (SD)*. IVIg, intravenous immunoglobin